NYSE · Health Care

The Cigna Group

Q: Who are The Cigna Group's main competitors?

UnitedHealth Group is the dominant integrated health insurer and PBM competitor, with its Optum arm mirroring Evernorth's structure. CVS Health, through its Aetna insurance and Caremark PBM divisions, is a direct rival across multiple Cigna segments. Elevance Health (formerly Anthem) competes in group health insurance. In standalone PBM, Prime Therapeutics also competes for employer and health plan contracts that Express Scripts pursues.

Q: Does The Cigna Group pay dividends?

Cigna pays a quarterly dividend that has grown consistently since the company reinstated and then expanded its dividend program following the Express Scripts acquisition in 2018. With a yield typically around 2%, the dividend reflects a company balancing significant buyback activity alongside income returns. Management has stated a commitment to growing the dividend annually, supported by the recurring nature of PBM and health insurance cash flows.

Q: How much does CI stock cost right now?

CI is currently trading at $297.50, up 1.33% in today's session. Over the past 52 weeks, the stock has traded between a low of $255.53 and a high of $316.27. The current price represents 69% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Q: What is the analyst consensus for CI?

Among 34 analysts covering CI, the consensus rating is Buy — 25 rate it a buy, 9 hold, and 0 sell. The average price target sits at $84.17, implying 72% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Q: Does The Cigna Group make money?

The Cigna Group generated $277.74B in revenue during fiscal year 2026, with $6.02B reaching the bottom line as net income. The net profit margin of 2.2% reflects the competitive nature of its industry.

Q: Is CI stock expensive based on earnings?

CI trades at a P/E ratio of 12.42 on trailing earnings of $24.13 per share. That's below the S&P 500 average, suggesting the market may see limited growth or is pricing in sector-specific risks. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Q: Is CI stock going up or down?

CI has delivered positive returns over the past year, though performance varies across timeframes. Returns by timeframe: +0.78% (1W), +5.00% (1M), +8.63% (3M), -1.07% (6M), +15.24% (1Y), +6.58% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether CI is outperforming or lagging the broader market.

S&P 500 Large-Cap Stocks Blue Chip Stocks Healthcare Stocks Best Dividend Stocks

$297.50

+3.91 (+1.33%)

Day Range $291.57 — $298.05

52W Range $255.53 — $316.27

Performance

1D —

1W +0.78%

1M +5.00%

3M +8.63%

6M -1.07%

1Y +15.24%

YTD +6.58%

Open$296.00

Previous Close$293.59

Day High$298.05

Day Low$291.57

52W High$316.27

52W Low$255.53

Volume—

Avg Volume1.65M

Market Cap79.66B

P/E Ratio12.42

EPS$24.13

SectorHealth Care

Technical Indicators

Full analysis →

SMA 50 $285.81 Above

SMA 200 $282.22 Above

RSI (14) 46.6 Neutral

Trend Golden Cross Bullish

Analyst Ratings

Buy

34 analysts

25 Buy 9 Hold 0 Sell

Price Target -71.7% upside

Current
$297.50

Target
$84.17

$52.89 $84.17 avg $131.15

Key Financials

	FY 2026	FY 2025	FY 2024
Revenue	277.74B	241.41B	20.79B
Net Income	6.02B	4.71B	3.82B
Profit Margin	2.2%	2.1%	18.4%
EBITDA	11.07B	9.14B	5.23B
Free Cash Flow	—	—	3.42B
Rev Growth	+15.1%	+15.1%	+10.3%
Debt/Equity	0.75	0.75	0.24

Dividend

Dividend Yield1.74%

Annual Dividend$6.00

Payout Ratio27.0%

Frequencyquarterly

Ex-DividendApr 21, 2026

Pay DateMay 2, 2026

Recent Insider Activity

All Insiders →

Date	Insider	Type	Shares	Price	Value
Mar 3	Jones Nicole S	Sale	32,647	$288.91	$9.43M
Mar 3	Neville Everett	Sale	5,670	$288.91	$1.64M
Nov 3	Cordani David	Buy	157,935	$241.88	$38.20M
Oct 7	Evanko Brian C	Exercise	56,550	$139.22	$7.87M
Oct 7	Evanko Brian C	Sale	51,182	$300.00	$15.35M

About The Cigna Group

The Cigna Group is a global health services company that provides insurance and related products and services, headquartered in Bloomfield, Connecticut. The company operates through Evernorth Health Services, which includes pharmacy benefit management and care delivery services, and Cigna Healthcare, which offers medical, dental, disability, and life insurance. Cigna serves millions of customers worldwide through employer-sponsored plans, government programs, and individual coverage. The company focuses on improving health outcomes and affordability through integrated health services and innovative care delivery models.

Health Care Peers

Symbol	Name	Price	Change	P/E	Mkt Cap
UNH	UnitedHealth Group Inc	$398.69	+1.15%	23.0	364.99B
ABT	Abbott Laboratories	$110.39	+0.42%	40.9	192.04B
ISRG	Intuitive Surgical Inc	$461.87	+2.00%	54.9	162.41B
SYK	Stryker Corp	$327.51	+0.50%	34.0	123.21B
MDT	Medtronic Plc	$101.80	-2.90%	25.6	134.11B
MCK	Mckesson Corp	$1,065.46	+0.44%	26.7	122.62B

CI Frequently Asked Questions

What does The Cigna Group do?

Cigna's largest revenue driver is its Evernorth division, which functions primarily as a pharmacy benefit manager — it negotiates drug prices on behalf of health plan sponsors, processes prescriptions through its Express Scripts network, and provides specialty pharmacy services. This makes it less dependent on medical insurance underwriting risk than traditional health insurers. The Cigna Healthcare segment underwrites employer-sponsored medical, dental, and disability coverage. The combination gives Cigna reach across both benefits administration and direct insurance.

Is CI stock a good investment?

Cigna's PBM-heavy model at Evernorth provides more predictable fee-based earnings than pure insurance underwriting, though pharmacy benefit management faces political scrutiny over drug pricing practices, which represents a regulatory risk. Medical cost inflation and the accuracy of actuarial assumptions drive profitability in the health insurance segment. The stock has traded at a discount to some healthcare peers, which investors attribute either to PBM regulatory uncertainty or a complex corporate structure. Consistent buybacks have reduced the share count steadily.

Who are The Cigna Group's main competitors?

UnitedHealth Group is the dominant integrated health insurer and PBM competitor, with its Optum arm mirroring Evernorth's structure. CVS Health, through its Aetna insurance and Caremark PBM divisions, is a direct rival across multiple Cigna segments. Elevance Health (formerly Anthem) competes in group health insurance. In standalone PBM, Prime Therapeutics also competes for employer and health plan contracts that Express Scripts pursues.

Does The Cigna Group pay dividends?

Cigna pays a quarterly dividend that has grown consistently since the company reinstated and then expanded its dividend program following the Express Scripts acquisition in 2018. With a yield typically around 2%, the dividend reflects a company balancing significant buyback activity alongside income returns. Management has stated a commitment to growing the dividend annually, supported by the recurring nature of PBM and health insurance cash flows.

How much does CI stock cost right now?

CI is currently trading at $297.50, up 1.33% in today's session. Over the past 52 weeks, the stock has traded between a low of $255.53 and a high of $316.27. The current price represents 69% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

What is the analyst consensus for CI?

Among 34 analysts covering CI, the consensus rating is Buy — 25 rate it a buy, 9 hold, and 0 sell. The average price target sits at $84.17, implying 72% downside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Does The Cigna Group make money?

The Cigna Group generated $277.74B in revenue during fiscal year 2026, with $6.02B reaching the bottom line as net income. The net profit margin of 2.2% reflects the competitive nature of its industry.

Is CI stock expensive based on earnings?

CI trades at a P/E ratio of 12.42 on trailing earnings of $24.13 per share. That's below the S&P 500 average, suggesting the market may see limited growth or is pricing in sector-specific risks. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Is CI stock going up or down?

CI has delivered positive returns over the past year, though performance varies across timeframes. Returns by timeframe: +0.78% (1W), +5.00% (1M), +8.63% (3M), -1.07% (6M), +15.24% (1Y), +6.58% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether CI is outperforming or lagging the broader market.